Rituximab in maintaining remission in adults with podocytopathy

• DOI: 10.1111/nep.13717
• Publication Date: 2020-04-16T08:55:10Z
• Authors: Raja Ramachandran; Joyita Bharati; Ritambhra Nada; Ranjana Minz; Harbir S. Kohli
• Keywords: Adult; Male; Nephrotic Syndrome; Glomerulosclerosis, Focal Segmental; Podocytes; Nephrosis, Lipoid; Calcineurin Inhibitors; Remission Induction; India; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Recurrence; Outcome Assessment, Health Care; Humans; Female; Steroids; Prospective Studies; Age of Onset; Rituximab; Immunosuppressive Agents

Abstract Rituximab is currently used after the conventional agents have failed in management of steroid‐dependent (SD)/ steroid‐resistant (SR) podocytopathies and a safer toxicity profile. We report 53 adults with who were managed effectively CD19‐targeted rituximab therapy. Methods This was prospective study carried out at tertiary care centre India between January 2014 June 2019. Adults 16 60 years SD, frequently relapsing (FR), SR nephrotic syndrome (NS) due to podocytopathy received approach. Primary outcome: Percentage patients remission 6 12 months. Secondary last follow‐up, dose adverse events Results Fifty‐three SD/FR/SR NS rituximab. The median age time first injection 30.09 ± 13.21 (16.53) years. At infusion, all steroids and/or calcineurin inhibitors (CNIs). Fifty (94.33%) end months follow‐up (median: 36 months). mean total 1 year 788.7 128.1 (6 001 100) mg. (median months), 42 (79%) did not require any additional CNI or No serious noted. Conclusion therapy safe efficacious SD/SR adult podocytopathy. Also, effective maintaining treatment naïve SD FR